GlassScriptPhysician profile
Jatinder Chopra
NPI 1659387652
$12,658.77
in general payments reported to CMS, 2019-2025
36 companies · $2,175 in 2025
The $2,175 reported for 2025 was more than what 77% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,763 · 2020: $675 · 2021: $1,581 · 2022: $2,132 · 2023: $1,931 · 2024: $2,402 · 2025: $2,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,507.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,203.38 | 2019-2025 | Breztri, Farxiga, Tezspire |
| Novo Nordisk INC | $2,594.16 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $1,072.16 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $732.90 | 2020-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amgen INC. | $621.73 | 2022-2025 | Repatha, Otezla, Tezspire |
| Mylan Specialty L.P. | $343.97 | 2019-2024 | Yupelri |
| Amarin Pharma, INC. | $277.59 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.19 | 2021-2025 | Ofev, Jardiance |
| Abbvie INC. | $242.00 | 2023-2025 | Ubrelvy |
| Idorsia Pharmaceuticals US INC | $214.15 | 2023-2024 | Quviviq |
| Alk-Abello, INC | $177.56 | 2023 | Grastek, Ragwitek, Odactra |
| Allergan, INC. | $159.00 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $148.10 | 2019-2020 | |
| Abbott Laboratories | $141.53 | 2022 | |
| Avanir Pharmaceuticals, INC. | $140.99 | 2019 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $128.08 | 2025 | Brixadi |
| Corcept Therapeutics | $127.73 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.67 | 2023 | |
| Daiichi Sankyo INC. | $122.98 | 2024 | Injectafer |
| Bio Products Laboratory USA, INC. | $115.14 | 2023 | Gammaplex, Coagadex |
| Lexicon Pharmaceuticals, INC. | $111.30 | 2024 | Inpefa |
| Dynavax Technologies Corporation | $106.68 | 2024 | Heplisav-B |
| Merck Sharp & Dohme LLC | $102.19 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.47 | 2022 | |
| Exact Sciences Corporation | $53.88 | 2023-2024 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $51.53 | 2020-2021 | |
| Pfizer INC. | $33.30 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $30.42 | 2019 | |
| Coopersurgical, INC. | $26.25 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.18 | 2019 | |
| Agile Therapeutics, INC. | $20.31 | 2024 | Twirla |
| Sanofi-Aventis U.S. LLC | $19.56 | 2019 | |
| Sumitomo Pharma America, INC. | $17.10 | 2024 | Myfembree |
| Eisai INC. | $17.08 | 2021 | |
| Hologic Sales and Service, LLC | $15.37 | 2025 | Thinprep 2000 Processor |
| Phadia US INC. | $14.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jatinder Chopra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.